NASDAQ:VECT

VectivBio Competitors

$13.48
-0.03 (-0.22 %)
(As of 05/11/2021 02:44 PM ET)
Add
Compare
Today's Range
$13.24
$13.98
50-Day Range N/A
52-Week Range
$13.20
$37.70
Volume271 shs
Average Volume92,232 shs
Market Capitalization$458.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

VectivBio (NASDAQ:VECT) Vs. IMCR, BCAB, EWTX, CGEM, NRIX, and KNTE

Should you be buying VECT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to VectivBio, including Immunocore (IMCR), BioAtla (BCAB), Edgewise Therapeutics (EWTX), Cullinan Oncology (CGEM), Nurix Therapeutics (NRIX), and Kinnate Biopharma (KNTE).

VectivBio (NASDAQ:VECT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VectivBio and Immunocore, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VectivBio00403.00
Immunocore01202.67

VectivBio presently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Immunocore has a consensus target price of $54.3333, suggesting a potential upside of 34.66%. Given VectivBio's stronger consensus rating and higher possible upside, equities analysts plainly believe VectivBio is more favorable than Immunocore.

Profitability

This table compares VectivBio and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VectivBioN/AN/AN/A
ImmunocoreN/AN/AN/A

Earnings & Valuation

This table compares VectivBio and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VectivBioN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Summary

VectivBio beats Immunocore on 3 of the 3 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares VectivBio and BioAtla's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VectivBioN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares VectivBio and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VectivBioN/AN/AN/A
BioAtlaN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VectivBio and BioAtla, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VectivBio00403.00
BioAtla00403.00

VectivBio presently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. BioAtla has a consensus target price of $62.75, suggesting a potential upside of 33.03%. Given VectivBio's higher possible upside, equities analysts plainly believe VectivBio is more favorable than BioAtla.

Summary

VectivBio beats BioAtla on 1 of the 1 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Edgewise Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VectivBioN/AN/AN/AN/AN/A
Edgewise TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares VectivBio and Edgewise Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VectivBioN/AN/AN/A
Edgewise TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for VectivBio and Edgewise Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VectivBio00403.00
Edgewise Therapeutics01302.75

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Edgewise Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 27.61%. Given VectivBio's stronger consensus rating and higher probable upside, analysts plainly believe VectivBio is more favorable than Edgewise Therapeutics.

Summary

VectivBio beats Edgewise Therapeutics on 3 of the 3 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Cullinan Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VectivBioN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Profitability

This table compares VectivBio and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VectivBioN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for VectivBio and Cullinan Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VectivBio00403.00
Cullinan Oncology00403.00

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Cullinan Oncology has a consensus target price of $48.75, suggesting a potential upside of 70.10%. Given VectivBio's higher probable upside, analysts plainly believe VectivBio is more favorable than Cullinan Oncology.

Summary

VectivBio beats Cullinan Oncology on 1 of the 1 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Nurix Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VectivBioN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares VectivBio and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VectivBioN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Institutional & Insider Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for VectivBio and Nurix Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VectivBio00403.00
Nurix Therapeutics00703.00

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Nurix Therapeutics has a consensus target price of $46.00, suggesting a potential upside of 69.18%. Given VectivBio's higher probable upside, analysts plainly believe VectivBio is more favorable than Nurix Therapeutics.

Summary

Nurix Therapeutics beats VectivBio on 2 of the 3 factors compared between the two stocks.

VectivBio (NASDAQ:VECT) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares VectivBio and Kinnate Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VectivBioN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for VectivBio and Kinnate Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VectivBio00403.00
Kinnate Biopharma00403.00

VectivBio currently has a consensus target price of $23.6667, suggesting a potential upside of 75.57%. Kinnate Biopharma has a consensus target price of $52.00, suggesting a potential upside of 121.75%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than VectivBio.

Profitability

This table compares VectivBio and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VectivBioN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Summary

Kinnate Biopharma beats VectivBio on 1 of the 1 factors compared between the two stocks.


VectivBio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Immunocore logo
IMCR
Immunocore
1.3$41.19-2.5%$1.73 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.7$47.00-2.1%$1.55 billionN/A0.00
EWTX
Edgewise Therapeutics
1.8$26.14-3.1%$1.28 billionN/A0.00Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$28.66-0.1%$1.25 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$27.12-3.5%$1.16 billionN/A0.00Gap Down
KNTE
Kinnate Biopharma
1.7$23.32-0.7%$1.02 billionN/A0.00News Coverage
STEM
Stem
0.0$19.49-0.6%$928.75 millionN/A0.00News Coverage
Gap Down
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$26.83-1.2%$924.93 millionN/A0.00Gap Down
CNTB
Connect Biopharma
1.7$14.63-4.4%$878.09 millionN/A0.00
Pharming Group logo
PHAR
Pharming Group
0.0$13.20-0.0%$846.50 millionN/A0.00
Vor Biopharma logo
VOR
Vor Biopharma
1.6$23.40-5.2%$823.87 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$29.49-1.8%$801.09 millionN/A0.00News Coverage
Gap Up
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$20.02-9.6%$797.04 millionN/A0.00Gap Down
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.43-0.5%$783.06 millionN/A0.00Upcoming Earnings
Analyst Report
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$11.00-0.2%$738.00 millionN/A0.00News Coverage
Gap Down
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.66-1.8%$708.76 millionN/A0.00News Coverage
Gap Up
FNCH
Finch Therapeutics Group
2.0$12.52-1.0%$584.60 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.16-1.7%$547.00 millionN/A0.00
ACHL
Achilles Therapeutics plc American Depositary Shares
1.6$13.70-2.2%$544.34 millionN/A0.00Quiet Period Expiration
BMEA
Biomea Fusion
1.0$16.61-0.1%$478.41 millionN/A0.00Analyst Report
News Coverage
Gap Down
MIGI
Mawson Infrastructure Group
0.0$0.97-8.2%$471.73 millionN/A0.00Gap Down
RAIN
Rain Therapeutics
1.3$16.24-10.0%$463.81 millionN/A0.00Gap Down
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$9.36-15.2%$463.53 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.5$10.60-0.3%$424.05 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.31-1.3%$422.16 millionN/A0.00
SGTX
Sigilon Therapeutics
1.4$14.04-8.0%$407.36 millionN/A0.00Earnings Announcement
News Coverage
Gap Down
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$13.54-0.2%$398.33 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$15.28-1.8%$377.13 millionN/A0.00
PRTG
Portage Biotech
0.0$27.95-2.9%$347.39 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$10.23-5.9%$331.27 millionN/A0.00Gap Down
RPHM
Reneo Pharmaceuticals
2.0$13.00-3.2%$324.67 millionN/A0.00Analyst Report
News Coverage
IMPL
Impel NeuroPharma
0.3$14.32-3.8%$288.70 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.75-0.3%$286.15 millionN/A-2.67
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.44-0.2%$242.71 millionN/A-2.36Upcoming Earnings
VINC
Vincerx Pharma
1.0$16.42-2.8%$223.19 millionN/A0.00
Annovis Bio logo
ANVS
Annovis Bio
0.0$28.72-0.4%$198.75 millionN/A0.00News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$7.43-4.6%$176.56 millionN/A0.00Gap Down
LBPH
Longboard Pharmaceuticals
1.9$9.42-7.7%$171.71 millionN/A0.00News Coverage
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.23-0.4%$138.02 millionN/A0.00Gap Down
EVAX
Evaxion Biotech A/S
1.7$5.99-5.0%$120.76 millionN/A0.00Upcoming Earnings
Gap Down
GANX
Gain Therapeutics
1.7$9.80-2.3%$113.65 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$5.36-2.8%$104.45 millionN/A0.00News Coverage
Gap Down
VRDN
Viridian Therapeutics
1.7$17.04-2.9%$66.59 millionN/A0.00Earnings Announcement
News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$3.33-8.1%$66.56 millionN/A0.00
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$5.22-5.0%$55.13 millionN/A0.00Gap Down
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.6$8.70-21.4%$54.64 millionN/A0.00Upcoming Earnings
Analyst Report
Gap Down
CUBT
Curative Biotechnology
0.0$0.12-0.0%$45.88 millionN/A0.00
CMMB
Chemomab Therapeutics
1.7$17.79-6.4%$44.22 millionN/A0.00Upcoming Earnings
Gap Down
VIRI
Virios Therapeutics
1.3$4.96-0.6%$41.32 millionN/A0.00Upcoming Earnings
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29-2.7%$39.81 millionN/A0.00Gap Down
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.